Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Other Operating Expenses (2021 - 2025)

Historic Other Operating Expenses for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $1.1 million.

  • Aligos Therapeutics' Other Operating Expenses rose 159.18% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 905.78%. This contributed to the annual value of $4.4 million for FY2024, which is 2913.25% up from last year.
  • As of Q3 2025, Aligos Therapeutics' Other Operating Expenses stood at $1.1 million, which was up 159.18% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Aligos Therapeutics' Other Operating Expenses ranged from a high of $1.6 million in Q1 2024 and a low of -$225000.0 during Q2 2021
  • For the 5-year period, Aligos Therapeutics' Other Operating Expenses averaged around $673842.1, with its median value being $845000.0 (2022).
  • Its Other Operating Expenses has fluctuated over the past 5 years, first plummeted by 10450.45% in 2022, then skyrocketed by 2014000.0% in 2023.
  • Quarter analysis of 5 years shows Aligos Therapeutics' Other Operating Expenses stood at $176000.0 in 2021, then soared by 380.11% to $845000.0 in 2022, then tumbled by 71.12% to $244000.0 in 2023, then soared by 134.84% to $573000.0 in 2024, then skyrocketed by 89.35% to $1.1 million in 2025.
  • Its Other Operating Expenses stands at $1.1 million for Q3 2025, versus $1.2 million for Q2 2025 and $880000.0 for Q1 2025.